Anika Therapeutics Names Potter as Chief Financial Officer.Business Editors and Medical Writers WOBURN, Mass.--(BW HealthWire)--April 4, 2000 Anika Therapeutics, Inc. (Nasdaq:ANIK ANIK Canadian COMSAT ) today announced Douglas R. Potter has joined the company as chief financial officer. Potter, 49, comes to Anika with more than 25 years experience in finance and accounting. Most recently, he was vice president and chief financial officer of Dynamics Research Corporation Dynamics Research Corporation (NASDAQ: DRCO) is a United States-based publicly held defense contractor. DRC was founded in 1955 by a small group of engineers from the Charles Stark Draper Laboratory of the Massachusetts Institute of Technology. (Nasdaq:DRCO), a company with annual revenues of nearly $190 million that provides information technology services and manufactures precision measurement and control products. Before joining Dynamics Research in 1993, Potter was vice president, treasurer and chief financial officer of SofTech, Inc., a public company engaged in software development and information technology services. He was also employed for 10 years with the accounting firm PricewaterhouseCoopers. Potter is a certified public accountant Certified Public Accountant (CPA) An accountant who has met certain standards, including experience, age, and licensing, and passed exams in a particular state. and is a member of the Financial Executives Institute and the Treasurers Club of Boston. He holds a master's degree in business administration from Boston University and a bachelor's degree from Purdue University. "Doug is an excellent addition to our management team," said J. Melville Engle, chairman, president and chief executive officer. "He has a strong background in finance and highly complementary experience that will be of great help to us as we move forward. We are extremely excited to have an executive of his stature among our ranks and look forward to the immediate and long-term value he will bring to the company." Anika Therapeutics, Inc. (www.anikatherapeutics.com) develops, manufactures and commercializes therapeutic products and devices intended to promote the repair, protection and healing of bone, cartilage and soft tissue. These products are based on hyaluronic acid hyaluronic acid: see mucopolysaccharide. Hyaluronic acid A polysaccharide which is an integral part of the gel-like substance of animal connective tissue; it supposedly serves as a lubricant and shock absorbent in the joints. (HA), a naturally occurring, biocompatible biocompatible /bio·com·pat·i·ble/ (-kom-pat´i-b'l) being harmonious with life; not having toxic or injurious effects on biological function. polymer found throughout the body. These include ORTHOVISC(R), a treatment for osteoarthritis osteoarthritis or osteoarthrosis or degenerative joint disease Most common joint disorder, afflicting over 80% of those who reach age 70. It does not involve excessive inflammation and may have no symptoms, especially at first. of the knee (not approved for sale in the U.S.), and HYVISC(R), which is marketed in the U.S. by Boehringer Ingelheim Vetmedica, Inc. for the treatment of equine osteoarthritis. Anika also manufactures AMVISC(R) and AMVISC(R) Plus, HA viscoelastic Adj. 1. viscoelastic - having viscous as well as elastic properties natural philosophy, physics - the science of matter and energy and their interactions; "his favorite subject was physics" products for ophthalmic surgery, for Bausch & Lomb Surgical. Therapies currently under development include INCERT(R), a family of HA products designed to prevent post-surgical adhesions. Anika is also collaborating with Orquest, Inc. to manufacture OSSIGEL(R), an injectable formulation of basic fibroblast growth factor Basic fibroblast growth factor, also known as bFGF or FGF2, is a member of the fibroblast growth factor family. In normal tissue, basic fibroblast growth factor is present in basement membranes and in the subendothelial extracellular matrix of blood combined with HA designed to accelerate the healing of bone fractures. AMVISC(R) is a registered trademark of Bausch & Lomb Incorporated. OSSIGEL(R) is a registered trademark of Orquest, Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion